

BUY
 TP: Rs 650 | ▲ 40%

PRINCE PIPES & FITTINGS

Building Materials

08 November 2024

Mixed Q2FY25; market share gain at the cost of inferior margin

- PRINCIPIP appears to have gained market share in Q2FY25 even after tightening the credit period for its dealers
- EBITDA margin to remain weak in the near future due to aggressive pricing strategy; but medium-term guidance of 12-13% remains intact
- Maintain BUY on strong earnings prospects and reasonable valuations; TP cut by 13% to Rs 650

Utkarsh Nopany
 research@bobcaps.in

Result snapshot: PRINCIPIP topline came broadly in line with our estimate (-1%), but there was a sharp miss on EBITDA (-32%) for Q2FY25 due to margin pressure (-230bps QoQ to 7.3%) as the company preferred to grow its market share by providing trade incentives of 2% to its dealers in a weak market condition, and booked inventory loss of Rs 120mn-150mn. Overall, PRINCIPIP’s revenue/EBITDA/APAT de-grew by -5.2%/-51.5%/-77.8% YoY in Q2FY25.

Key highlights: PRINCIPIP appears to have gained market share in Q2FY25 as it has posted relatively better volume growth YoY compared to its major peers (APOLP standalone: -17.0%; SI: -0.7%; PRINCIPIP: +4.3%; FNXP: +10.2%) even after tightening its collection period (from 71 days in Q4FY24 to 60 in Q1FY25 and 55 in Q2FY25). The company had net debt of Rs 0.81bn in Sep’24 vs net cash position of Rs 0.96bn in Jun’24 due to the sharp increase in inventory (from 70 days in Q1FY25 to 87 days in Q2FY25) and higher capex outlay.

Outlook: The company targets growing its pipe volume at a modest pace of 8-10% YoY in FY25 (vs 8.6% YoY in H1FY25). We believe PRINCIPIP’s EBITDA margin may remain weak in the near future as it has preferred to grow market share by pursuing aggressive pricing strategy in weak market conditions, but management maintains its EBITDA margin guidance of 12-13% over the medium term. The Bihar greenfield pipe project (with 55ktpa capacity) is expected to be operational by Mar’25 (Jan’25 earlier). Capex guidance for FY25 is Rs 3.3bn-3.5bn. The company expects its ROCE to improve to 15-20% over the medium term.

Maintain BUY; TP cut by 13% to Rs 650: We maintain our BUY rating on the stock due to (a) strong earnings growth prospects (EPS to grow at a healthy 16.3% CAGR over FY24-FY27E), and (b) reasonable valuations (trades at 28.8x on 1Y forward P/E vs 5Y average P/E of 35.6x). We have cut our TP to Rs 650 (from Rs 750) due to the downward revision of our EPS estimates (-31.7%/-21.1%/-18.3% for FY25E/FY26E/FY27E) based on the weak Q2FY25 result. Our target P/E remains unchanged at 30x on Sep’26 estimates (Jun’26 earlier).

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	PRINCIPIP IN/Rs 465
Market cap	US\$ 608.7mn
Free float	39%
3M ADV	US\$ 1.2mn
52wk high/low	Rs 776/Rs 461
Promoter/FPI/DII	61%/7%/18%


Source: NSE | Price as of 8 Nov 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	25,687	27,762	33,362
EBITDA (Rs mn)	3,107	2,813	3,987
Adj. net profit (Rs mn)	1,716	1,331	2,089
Adj. EPS (Rs)	15.5	12.0	18.9
Consensus EPS (Rs)	15.5	16.5	22.7
Adj. ROAE (%)	11.8	8.3	12.0
Adj. P/E (x)	29.9	38.6	24.6
EV/EBITDA (x)	16.7	18.5	12.6
Adj. EPS growth (%)	40.4	(22.4)	56.9

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



Fig 1 – Quarterly performance - Standalone

(Rs mn)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	H1FY25	H1FY24	YoY (%)	BOBCAPS Q2FY25E	Variance (%)
Operating income	6,221	6,565	(5.2)	6,045	2.9	12,265	12,100	1.4	6,311	(1.4)
Raw-Material expense	4,542	4,511	0.7	4,370	3.9	8,911	8,653	3.0	-	-
Gross Profit	1,679	2,054	(18.2)	1,675	0.2	3,354	3,447	(2.7)	-	-
Employee expense	446	405	10.2	382	16.9	828	725	14.1	-	-
Other expense	776	707	9.8	710	9.2	1,486	1,327	12.0	-	-
EBITDA	457	942	(51.5)	583	(21.6)	1,040	1,395	(25.5)	675	(32.3)
D&A	276	225	22.3	257	7.0	533	443	20.2	-	-
EBIT	181	716	(74.7)	325	(44.3)	507	951	(46.7)	-	-
Interest cost	16	7	137.4	14	13.1	31	24	26.8	-	-
Other income	39	219	(82.0)	26	53.5	65	257	(74.7)	-	-
PBT	204	928	(78.0)	337	(39.3)	541	1,184	(54.3)	-	-
Tax	57	222	(74.2)	90	(36.3)	147	281	(47.7)	-	-
Reported PAT	147	706	(79.2)	247	(40.4)	394	903	(56.4)	-	-
Adjusted PAT	147	663	(77.8)	247	(40.4)	394	860	(54.2)	331	(55.6)
As % of net revenues			(bps)		(bps)			(bps)		
Gross margin	27.0	31.3	(429)	27.7	(72)	27.3	28.5	(114)	-	-
Employee cost	7.2	6.2	101	6.3	86	6.7	6.0	76	-	-
Other cost	12.5	10.8	170	11.8	72	12.1	11.0	115	-	-
EBITDA margin	7.3	14.3	(700)	9.6	(230)	8.5	11.5	(305)	-	-
Tax rate	28.0	23.9	410	26.7	131	27.2	23.8	343	-	-
APAT margin	2.4	10.1	(774)	4.1	(172)	3.2	7.1	(389)	-	-

Source: Company, BOBCAPS Research

Fig 2 – Key operating metrics


Particulars	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	H1FY25	H1FY24	YoY (%)
Sales Volumes (KTPA)	43.3	41.5	4.3	42.2	2.7	85	37	130.1
Realisation (Rs/kg)	143.7	158.1	(9.1)	143.3	0.2	143	326	(55.9)
EBITDA per unit (Rs/kg)	10.6	22.7	(53.5)	13.8	(23.6)	12.2	37.5	(67.6)
Inventory (days)	87	57	-	70	-	-	-	-
Debtor (days)	55	59	-	60	-	-	-	-
Creditor (days)	36	39	-	36	-	-	-	-
Operating cycle (days)	106	77	-	94	-	-	-	-

Source: Company, BOBCAPS Research

Earnings call highlights


- **Pipe demand scenario:** The company posted weak volume growth of 4.3% YoY in Q2FY25 due to the impact of destocking in the channel on account of volatile PVC resin prices. The EBITDA margin fell sharply (-230bps QoQ to 7.3%) in Q2FY25 as the company preferred to grow its market share by providing trade incentives of 2% to its dealers in weak market conditions and booked inventory loss of Rs 120mn-150mn. The company has observed weak pipe demand in the month of Oct'24, but expects demand to pick-up for channel refilling in anticipation of hardening of PVC resin prices in the near future.
- **Guidance:** Management has guided for a moderate pipe volume growth target of 8-10% YoY in FY25 (vs +8.6% in H1FY25). The company continues to provide additional trade incentives of 2% to grow its market share, but it may be withdrawn post improvement in demand conditions. EBITDA margin is expected to return to the normal level of 12-13% over the next few quarters. The company expects its ROCE to improve to 15-20% over the medium term.
- **Ad spend:** Ad spend as a proportion of sales stood at 2.5% of sales in Q2FY25. The company expects to maintain a similar run rate (at 2.5%) for FY25.
- **Working capital:** PRINCEPIP's debtor period fell from 60 days in Q1FY25 to 55 days in Q2FY25 and aims to cut it further to below 50 days by the end of FY25 to improve its cash flow conversion cycle. The inventory period rose from 70 days in Q1FY25 to 87 days in Q2FY25, but the company aims to bring it down to 60-70 days in future.
- **Capex:** The company plans to spend Rs 3.3bn-3.5bn in FY25 (of which Rs 1.7bn would be spent on Bihar greenfield project, Rs 0.3bn-0.35bn for debottlenecking pipe capacity at the existing site, Rs 0.8bn-0.9bn for maintenance capex purpose, and Rs 0.5bn for the bathware division (including acquisition cost of the second phase of the Aquel plant of Rs 0.43bn). The Bihar pipe project (capacity increased to 55KTPA) is expected to be operational by Mar'25 (Jan'25 earlier).
- **Bathware:** The segment reported operating loss of Rs 30mn-40mn on revenue of Rs 70mn in Q2FY25. The company expects this segment to clock a revenue of Rs 250mn+ in FY25 and reach breakeven point by Q3FY26.
- **Water tank:** Revenue was Rs 120mn in Q2FY25.

Fig 3 – PRINCPIP’s volumes grew by 4.3% YoY (5Y CAGR: +4.6%) in Q2FY25




Source: Company, BOBCAPS Research

Fig 4 – EBITDA margin fell sharply by 230bps QoQ to 7.3% in Q2FY25




Source: Company, BOBCAPS Research

Fig 5 – PRINCPIP had a net debt of Rs 0.81bn in Sep’24 vs net cash of Rs 0.96bn in Jun’24...




Source: Company, BOBCAPS Research

Fig 6 – ... due to sharp increase in the inventory and higher capex outlay




Source: Company, BOBCAPS Research

Fig 7 – PRINCPIP’s EPS is forecast to grow at 15% CAGR over FY24-FY27E



Source: Company, BOBCAPS Research

Fig 8 – ROE is projected to improve gradually from 11.8% in FY24 to 13.5% in FY27E



Source: Company, BOBCAPS Research

Valuation methodology

We maintain our BUY rating on the stock due to (a) strong earnings growth prospects (EPS to grow at a healthy 16.3% CAGR over FY24-FY27E), and (b) reasonable valuations (trades at 28.8x on 1Y forward P/E vs 5Y average P/E of 35.6x).


We have cut our TP to Rs 650 (from Rs 750) due to the downward revision of our EPS estimates (-31.7%/-21.1%/-18.3% for FY25/FY26/FY27) based on the weak Q2FY25 result. Our target P/E remains unchanged at 30x on Sep'26 estimates.

Fig 9 – Revised estimates

Standalone (Rs mn)	New			Old			Change (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Operating income	27,762	33,362	38,058	28,448	33,696	38,547	(2.4)	(1.0)	(1.3)
EBITDA	2,813	3,987	4,801	3,530	4,527	5,403	(20.3)	(11.9)	(11.2)
EBITDA Margin (%)	10.1	12.0	12.6	12.4	13.4	14.0	(228bps)	(148bps)	(140bps)
Adjusted PAT	1,331	2,089	2,622	1,950	2,649	3,209	(31.7)	(21.1)	(18.3)
EPS (Rs)	12.0	18.9	23.7	17.6	24.0	29.0	(31.7)	(21.1)	(18.3)

Source: BOBCAPS Research

Fig 10 – Trading at 28.0x on 1Y forward P/E vs 5Y average of 35.6x



Source: Bloomberg, BOBCAPS Research

Fig 11 – Key assumptions

Particulars	FY22A	FY23A	FY24A	FY25E	FY26E	FY27E
Sales Volume growth (%)	0.5	13.4	9.6	10.9	15.0	10.8
Realisation growth (%)	27.6	(10.1)	(13.5)	(2.5)	4.5	3.0
EBITDA per unit (Rs/kg)	30.1	16.0	18.0	14.7	18.1	19.7
Pre-tax ROIC (%)	32.5	13.4	16.3	10.3	14.0	15.7

Source: Company, BOBCAPS Research

Key risks

- Market share loss in plastic pipes along with weak return ratios.
- Increased exposure to group companies and significant cost/time overruns in the Bihar greenfield project.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Apollo Pipes	APOLP IN	0.2	512	550	HOLD
Astral	ASTRA IN	5.7	1,789	2,000	HOLD
Century Plyboards	CPBI IN	2.2	835	725	HOLD
Finolex Industries	FNXP IN	2.1	288	300	HOLD
Greenlam Industries	GRLM IN	0.8	556	530	HOLD
Greenpanel Industries	GREENP IN	0.5	372	365	HOLD
Greenply Industries	MTLM IN	0.5	356	380	HOLD
Hindware Home Innovation	HINDWARE IN	0.2	282	500	BUY
Kajaria Ceramics	KJC IN	2.3	1,201	1,450	HOLD
Prince Pipes & Fittings	PRINCP IN	0.6	465	650	BUY
Somany Ceramics	SOMC IN	0.3	683	850	BUY
Supreme Industries	SI IN	6.9	4,598	5,250	BUY

Source: BOBCAPS Research, NSE | Price as of 8 Nov 2024

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Total revenue	27,109	25,687	27,762	33,362	38,058
EBITDA	2,517	3,107	2,813	3,987	4,801
Depreciation	830	912	1,099	1,273	1,374
EBIT	1,687	2,196	1,714	2,714	3,426
Net interest inc./(exp.)	(110)	(65)	(64)	(66)	(66)
Other inc./(exp.)	86	161	144	143	143
Exceptional items	14	33	0	0	0
EBT	1,648	2,258	1,794	2,792	3,504
Income taxes	434	613	462	703	882
Extraordinary items	0	(179)	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	1,214	1,825	1,331	2,089	2,622
Adjustments	9	(109)	0	0	0
Adjusted net profit	1,223	1,716	1,331	2,089	2,622

Balance Sheet

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Accounts payables	3,202	2,491	2,832	3,404	3,883
Other current liabilities	794	1,659	1,659	1,659	1,659
Provisions	20	26	30	36	41
Debt funds	581	1,144	1,222	1,430	1,605
Other liabilities	305	467	467	467	467
Equity capital	1,106	1,106	1,106	1,106	1,106
Reserves & surplus	12,534	14,338	15,449	17,206	19,385
Shareholders' fund	13,640	15,444	16,554	18,311	20,491
Total liab. and equities	18,542	21,232	22,764	25,307	28,146
Cash and cash eq.	2,161	1,156	(680)	(1,285)	(1,154)
Accounts receivables	4,150	5,849	6,321	7,596	8,665
Inventories	4,256	4,379	4,726	5,626	6,431
Other current assets	684	1,081	1,229	1,476	1,683
Investments	3	3	3	3	3
Net fixed assets	6,750	7,736	10,137	10,864	11,490
CWIP	190	353	353	353	353
Intangible assets	101	240	240	240	240
Deferred tax assets, net	0	0	0	0	0
Other assets	246	435	435	435	435
Total assets	18,542	21,232	22,764	25,307	28,146

Cash Flows

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Cash flow from operations	3,645	558	1,728	1,441	2,321
Capital expenditures	(1,000)	(2,347)	(3,500)	(2,000)	(2,000)
Change in investments	14	0	0	0	0
Other investing cash flows	72	307	144	143	143
Cash flow from investing	(915)	(2,040)	(3,356)	(1,857)	(1,857)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(919)	563	77	208	175
Interest expenses	(110)	(65)	(64)	(66)	(66)
Dividends paid	0	(111)	(221)	(332)	(442)
Other financing cash flows	(227)	90	0	0	0
Cash flow from financing	(1,256)	478	(208)	(189)	(333)
Chg in cash & cash eq.	1,474	(1,005)	(1,836)	(606)	131
Closing cash & cash eq.	2,161	1,156	(680)	(1,285)	(1,155)

Per Share

Y/E 31 Mar (Rs)	FY23A	FY24A	FY25E	FY26E	FY27E
Reported EPS	11.0	16.5	12.0	18.9	23.7
Adjusted EPS	11.1	15.5	12.0	18.9	23.7
Dividend per share	0.0	1.0	2.0	3.0	4.0
Book value per share	123.4	139.7	149.7	165.6	185.3

Valuations Ratios

Y/E 31 Mar (x)	FY23A	FY24A	FY25E	FY26E	FY27E
EV/Sales	1.9	2.0	1.9	1.5	1.3
EV/EBITDA	20.5	16.7	18.5	12.6	10.2
Adjusted P/E	42.0	29.9	38.6	24.6	19.6
P/BV	3.8	3.3	3.1	2.8	2.5

DuPont Analysis

Y/E 31 Mar (%)	FY23A	FY24A	FY25E	FY26E	FY27E
Tax burden (Net profit/PBT)	74.2	76.0	74.2	74.8	74.8
Interest burden (PBT/EBIT)	97.7	102.9	104.7	102.8	102.3
EBIT margin (EBIT/Revenue)	6.2	8.5	6.2	8.1	9.0
Asset turnover (Rev./Avg TA)	146.2	121.0	122.0	131.8	135.2
Leverage (Avg TA/Avg Equity)	1.4	1.5	1.4	1.5	1.5
Adjusted ROAE	9.3	11.8	8.3	12.0	13.5

Ratio Analysis

Y/E 31 Mar	FY23A	FY24A	FY25E	FY26E	FY27E
YoY growth (%)					
Revenue	2.0	(5.2)	8.1	20.2	14.1
EBITDA	(39.9)	23.4	(9.5)	41.8	20.4
Adjusted EPS	(51.3)	40.4	(22.4)	56.9	25.5
Profitability & Return ratios (%)					
EBITDA margin	9.3	12.1	10.1	12.0	12.6
EBIT margin	6.2	8.5	6.2	8.1	9.0
Adjusted profit margin	4.5	6.7	4.8	6.3	6.9
Adjusted ROAE	9.3	11.8	8.3	12.0	13.5
ROCE	12.5	14.2	10.4	14.5	16.2
Working capital days (days)					
Receivables	56	83	83	83	83
Inventory	57	62	62	62	62
Payables	43	35	37	37	37
Ratios (x)					
Gross asset turnover	2.8	2.3	2.0	2.0	2.1
Current ratio	2.4	2.4	2.1	2.1	2.2
Net interest coverage ratio	15.3	33.8	26.9	41.4	52.3
Adjusted debt/equity	(0.1)	0.0	0.1	0.1	0.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (“US”) OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
 Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
 SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**
 Brand Name: **BOBCAPS**
 Trade Name: **www.barodaetrade.com**
 CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
 Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): PRINCE PIPES & FITTINGS (PRINCIPI IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.